Kras ?adenocarcinoma? mutation? new trial drugs with ins. & tissue eval. what is the doctor really saying to 70 year nsclc pat.9 month ..meets w/new cell grow

Clinical trial/newtx: He is talking about using some of the new targeted therapies that may work very well with relatively few side effects if the cell mutations in her type of lung cancer r the specific type that these drugs target. He may also b talking about a clinical trial.

Describing the Tumor: So it sounds like the oncologist has really just given you a lot of descriptors to help describe the tumor. The idea is that if we know this information we can select therapies that are more likely to work. For example, whether a patient has a k-ras mutation helps predict whether a tumor may be resistant to a certain drug.

KRAS: Kras is a gene involved in a pathway that controls cell growth. A mutationin the kras gene can lead to a propensity to develop lung cancer. There are several clinical trials that look at inhibitors in that pathway to treat patinets with advanced kras mutant lung cancer.